Please login to the form below

Not currently logged in
Email:
Password:

Stivarga

This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.

Another IO knockback as Tecentriq combo fails phase III trial

Another IO knockback as Tecentriq combo fails phase III trial

cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population.

Latest news

  • Pharma sales help Bayer escape the worst from a bumpy 2017 Pharma sales help Bayer escape the worst from a bumpy 2017

    The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.

  • NICE backs Pfizer’s Xeljanz for RA NICE backs Pfizer’s Xeljanz for RA

    Meanwhile, NICE has decided to remove Bayer ’s gastrointestinal stomach tumour (GIST) treatment Stivarga (regorafenib) from the cancer drugs fund (CDF) to make it routinely available to some patients on the

  • Bayer's Nexavar backed by NICE for liver cancer Bayer's Nexavar backed by NICE for liver cancer

    Amanda Cunnington, head of patient access at Bayer UK, said the company recently submitted its new HCC drug Stivarga (regorafenib) for review by NICE and the Scottish Medicines Consortium (SMC) "with

  • EMA clears Bayer's Stivarga for liver cancer EMA clears Bayer's Stivarga for liver cancer

    EMA clears Bayer's Stivarga for liver cancer. The multikinase inhibitor will treat patients with HCC. ... Nexavar is the only approved first-line treatment and Stivarga the only approved second-line therapy in Europe and the US for patients with HCC,"

  • FDA OK for Stivarga ends decade-long drought in liver cancer FDA OK for Stivarga ends decade-long drought in liver cancer

    FDA OK for Stivarga ends decade-long drought in liver cancer. Bayer's medicine wins US approval to treat hepatocellular carcinoma. ... Oral multikinase inhibitor Stivarga (regorafenib) has been cleared by the US regulator for patients with hepatocellular

More from news
Approximately 13 fully matching, plus 21 partially matching documents found.

Latest Intelligence

  • Deal Watch table for August 2013 Deal Watch table for August 2013

    Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.

  • Pharma deals during August 2013 Pharma deals during August 2013

    To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics